WO2008026149A1 - 1,4,5,6, 7,8-hexahydro-i^1s-triaza-azulene derivatives as orexin receptor antagonists - Google Patents
1,4,5,6, 7,8-hexahydro-i^1s-triaza-azulene derivatives as orexin receptor antagonists Download PDFInfo
- Publication number
- WO2008026149A1 WO2008026149A1 PCT/IB2007/053417 IB2007053417W WO2008026149A1 WO 2008026149 A1 WO2008026149 A1 WO 2008026149A1 IB 2007053417 W IB2007053417 W IB 2007053417W WO 2008026149 A1 WO2008026149 A1 WO 2008026149A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- disorders
- methyl
- phenyl
- ethyl
- pain
- Prior art date
Links
- 0 *c1n[n](*)c(CCCN)c1 Chemical compound *c1n[n](*)c(CCCN)c1 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N O=Cc1ccccc1 Chemical compound O=Cc1ccccc1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-N OC(/C=C/c1ccccc1)=O Chemical compound OC(/C=C/c1ccccc1)=O WBYWAXJHAXSJNI-VOTSOKGWSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N OC(CCc1ccccc1)=O Chemical compound OC(CCc1ccccc1)=O XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the present invention relates to novel compounds of formula (II) and their use as pharmaceuticals.
- the invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of formula (II), and especially their use as orexin receptor antagonists.
- Orexins are novel neuropeptides found in 1998 by two research groups, orexin A is a 33 amino acid peptide and orexin B is a 28 amino acid peptide (Sakurai T. et al., Cell, 1998, 92, 573-585). Orexins are produced in discrete neurons of the lateral hypothalamus and bind to the G- protein-coupled receptors (OXi and OX 2 receptors).
- the orexin-1 receptor (OXi) is selective for OX-A
- the orexin-2 receptor (OX 2 ) is capable to bind OX-A as well as OX-B.
- Orexins are found to stimulate food consumption in rats suggesting a physiological role for these peptides as mediators in the central feedback mechanism that regulates feeding behaviour (Sakurai T. et al., Cell, 1998, 92, 573-585). On the other hand, it was also observed that orexins regulate states of sleep and wakefulness opening potentially novel therapeutic approaches to narcolepsy as well as insomnia and other sleep disorders (Chemelli R.M. et al., Cell, 1999, 98, 437-451 ).
- Orexin receptors are found in the mammalian brain and may have numerous implications in pathologies as known from the literature.
- the present invention provides substituted 1 ,4,5,6,7,8-hexahydro-1 ,2,5-triaza- azulene derivatives, which are non-peptide antagonists of human orexin OXi and OX 2 receptors. These compounds are in particular of potential use in the treatment of e.g. eating disorders, drinking disorders, sleep disorders, or cognitive dysfunctions in psychiatric and neurologic disorders. Up to now, some low molecular weight compounds are known having a potential to antagonise either specifically OXi or OX 2 , or both receptors at the same time. In WO01/85693, Banyu Pharmaceuticals claimed N-acyltetrahydroisoquinoline derivatives. Other orexin receptor antagonists such as novel benzazepine derivatives are disclosed in WO02/051838.
- a first aspect of the invention consists of a compound of the general formula II, wherein the chirality is as depicted below, and
- Y represents -CH 2 -CH 2 -;
- R 1 represents a phenyl group, wherein the phenyl group can be mono-, di-, or trisubstituted, wherein the substituents are independently selected from the group consisting of (Ci -4 )alkyl, halogen and thfluoromethyl;
- R 2 represents (Ci -4 )alkyl;
- R 3 represents (Ci -4 )alkyl;
- R 4 represents a phenyl group, wherein the phenyl group is unsubstituted or independently mono-, di-, or trisubstituted wherein the substituents are independently selected from the group consisting of (Ci -4 )alkyl and halogen; R 5 represents (Ci -4 )alkyl.
- Also part of the invention are compounds of the formula (II) and pharmaceutically acceptable salts thereof.
- halogen means fluorine, chlorine or bromine and preferably fluorine or chlorine. In a further preferred embodiment of the invention the term “halogen” means fluorine.
- (Ci -4 )alkyl preferably means methyl, ethyl or butyl and more preferably ethyl.
- the phenyl group as described in the present invention may be independently mono-, di-, or trisubstituted wherein the substituents are independently selected from the group consisting of (Ci -4 )alkyl, halogen, and trifluoromethyl.
- substituents are independently selected from the group consisting of (Ci -4 )alkyl, halogen, and trifluoromethyl. Examples are phenyl, 3,5-difluoro-4-trifluoromethyl-phenyl, dimethyl-phenyl (e.g. 2,3- dimethyl-phenyl, 2,4-dimethyl-phenyl, 3,4-dimethyl-phenyl), 3,5-difluoro-4-methyl- phenyl, and 2-fluoro-4-trifluoromethyl-phenyl.
- R 1 preferably represents a phenyl group which is independently mono-, di-, or trisubstituted (preferred di-, or trisubstituted) wherein the substituents are independently selected from the group consisting of (Ci -4 )alkyl, halogen, and trifluoromethyl.
- the substituents are independently selected from the group consisting of methyl, ethyl, isopropyl, trifluoromethyl, fluorine and chlorine. More preferred, the substituents are independently selected from the group consisting of methyl, ethyl, trifluoromethyl, fluorine, and chlorine. Examples are 3,5-difluoro-4-trifluoromethyl-phenyl, dimethyl-phenyl (e.g.
- R 4 represents a phenyl group which is unsubstituted or independently mono-, di-, or trisubstituted wherein the substituents are independently selected from the group consisting of (Ci -4 )alkyl, and halogen.
- phenyl preferably means unsubstituted phenyl.
- salts refers to non-toxic, inorganic or organic acid and/or base addition salts. Reference can be made to "Salt selection for basic drugs", Int. J. Pharm. (1986), 33, 201-217.
- a further preferred embodiment of the invention are compounds of formula Il wherein
- Y represents -CH 2 -CH 2 -;
- R 1 represents a phenyl group, wherein the phenyl group can be mono-, di-, or trisubstituted, wherein the substituents are independently selected from methyl, ethyl, fluorine, chlorine and thfluoromethyl;
- R 2 represents (Ci -4 )alkyl;
- R 3 represents (Ci -4 )alkyl;
- R 4 represents a phenyl group, wherein the phenyl group is unsubstituted or independently mono-, di-, or trisubstituted wherein the substituents are independently selected from the group consisting of (Ci -4 )alkyl and halogen; R 5 represents (Ci -4 )alkyl.
- Y represents -CH 2 -CH 2 -;
- R 1 represents a phenyl group, wherein the phenyl group can be mono-, di-, or trisubstituted, wherein the substituents are independently selected from the group consisting of methyl, ethyl, fluorine, chlorine and thfluoromethyl;
- R 2 represents methyl;
- R 3 represents ethyl;
- R 4 represents a phenyl group;
- R 5 represents methyl.
- the compounds of Formula Il may contain one or more stereogenic or asymmetric centers, such as one or more asymmetric carbon atoms.
- the compounds of Formula Il may thus be present as mixtures of stereoisomers or preferably as pure stereoisomers. Mixtures of stereoisomers may be separated in a manner known to a person skilled in the art.
- the compounds specifically mentioned above contain two centers of chirality.
- the compounds of the general formula Il exhibit the following chirality: (R)-2' and (S)-4 or (R)-2' and (R)-4.
- the more preferred stereoisomers exhibit the chirality as depicted below:
- the compounds of formula Il and their pharmaceutically acceptable salts can be used as medicaments, e.g. in the form of pharmaceutical compositions for enteral or parental administration.
- the compounds of the general formula Il are useful for the treatment and/or prevention of the diseases mentioned herein.
- the invention relates to a method for the treatment and/or prevention of the diseases mentioned herein, said method comprising administering to a subject a pharmaceutically active amount of a compound of general formula II.
- the compounds according to formula (II) may be used for the preparation of a medicament, and are suitable, for the prevention or treatment of diseases selected from the group consisting of dysthymic disorders including major depression and cyclothymia, affective neurosis, all types of manic depressive disorders, delirium, psychotic disorders, schizophrenia, catatonic schizophrenia, delusional paranoia, adjustment disorders and all clusters of personality disorders; schizoaffective disorders; anxiety disorders including generalized anxiety, obsessive compulsive disorder, posttraumatic stress disorder, panic attacks, all types of phobic anxiety and avoidance; separation anxiety; all psychoactive substance use, abuse, seeking and reinstatement; all types of psychological or physical addictions, dissociative disorders including multiple personality syndromes and psychogenic amnesias; sexual and reproductive dysfunction; psychosexual dysfunction and addiction; tolerance to
- the compounds according to formula (II) may be used for the preparation of a medicament, and are suitable, for the prevention or treatment of diseases selected from the group consisting of all types of sleep disorders, of stress- related syndromes, of psychoactive substance use and abuse, of cognitive dysfunctions in the healthy population and in psychiatric and neurologic disorders, of eating or drinking disorders.
- Eating disorders may be defined as comprising metabolic dysfunction; dysregulated appetite control; compulsive obesities; emeto-bulimia or anorexia nervosa.
- Pathologically modified food intake may result from disturbed appetite (attraction or aversion for food); altered energy balance (intake vs.
- Drinking disorders include polydipsias in psychiatric disorders and all other types of excessive fluid intake.
- Sleep disorders include all types of parasomnias, insomnias, narcolepsy and other disorders of excessive sleepiness, sleep-related dystonias; restless leg syndrome; sleep apneas; jet-lag syndrome; shift-work syndrome, delayed or advanced sleep phase syndrome or insomnias related to psychiatric disorders.
- Insomnias are defined as comprising sleep disorders associated with aging; intermittent treatment of chronic insomnia; situational transient insomnia (new environment, noise) or short-term insomnia due to stress; grief; pain or illness.
- Insomnia also include stress-related syndromes including post-traumatic stress disorders as well as other types and subtypes of anxiety disorders such as generalized anxiety, obsessive compulsive disorder, panic attacks and all types of phobic anxiety and avoidance; psychoactive substance use, abuse, seeking and reinstatement are defined as all types of psychological or physical addictions and their related tolerance and dependence components.
- Cognitive dysfunctions include deficits in all types of attention, learning and memory functions occurring transiently or chronically in the normal, healthy, young, adult or aging population, and also occurring transiently or chronically in psychiatric, neurologic, cardiovascular and immune disorders.
- compounds according to formula (II) may be used for the preparation of a medicament, and are suitable, for the prevention or treatment of diseases selected from the group consisting of sleep disorders that comprises all types of insomnias, narcolepsy and other disorders of excessive sleepiness, sleep-related dystonias, restless leg syndrome, sleep apneas, jet-lag syndrome, shift-work syndrome, delayed or advanced sleep phase syndrome or insomnias related to psychiatric disorders.
- diseases selected from the group consisting of sleep disorders that comprises all types of insomnias, narcolepsy and other disorders of excessive sleepiness, sleep-related dystonias, restless leg syndrome, sleep apneas, jet-lag syndrome, shift-work syndrome, delayed or advanced sleep phase syndrome or insomnias related to psychiatric disorders.
- compounds of general formula (II) may be used for the preparation of a medicament, and are suitable, for the prevention or treatment of diseases selected from the group consisting of cognitive dysfunctions that comprise deficits in all types of attention, learning and memory functions occurring transiently or chronically in the normal, healthy, young, adult or aging population, and also occurring transiently or chronically in psychiatric, neurologic, cardiovascular and immune disorders.
- diseases selected from the group consisting of cognitive dysfunctions that comprise deficits in all types of attention, learning and memory functions occurring transiently or chronically in the normal, healthy, young, adult or aging population, and also occurring transiently or chronically in psychiatric, neurologic, cardiovascular and immune disorders.
- compounds of general formula (II) may be used for the preparation of a medicament, and are suitable, for the prevention or treatment of diseases selected from the group consisting of eating disorders that comprise metabolic dysfunction; dysregulated appetite control; compulsive obesities; emeto-bulimia or anorexia nervosa.
- compounds of general formula (II) may be used for the preparation of a medicament, and are suitable, for the prevention or treatment of diseases selected from the group consisting of psychoactive substance use and abuse that comprise all types of psychological or physical addictions and their related tolerance and dependence components.
- compositions can be effected in a manner which will be familiar to any person skilled in the art (see for example Mark Gibson, Editor, Pharmaceutical Preformulation and Formulation, IHS Health Group, Englewood, CO, USA, 2001 ; Remington, The Science and Practice of Pharmacy, 20th Edition, Philadelphia College of Pharmacy and Science; or Remington, The Science and Practice of Pharmacy, 21st Edition (2005), Part 5, "Pharmaceutical Manufacturing” [published by Lippincott Williams & Wilkins]) by bringing the described compounds of Formula (II) and their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.
- R 1 , R 2 , R 3 , R 4 , R 5 and Y are as defined in general formula Il above, X represents OH or Cl and Z represents Br or OTs;
- X represents OH or Cl and Z represents Br or OTs;
- the preparation of an example for intermediates IH is described in WO05/1 18548.
- the acylated Meldrum's acid derivative A reacted with the mono-substituted hydrazine B to give via a multi-step sequence (see Schemel and experimental part) the 3-(2,5-di-substituted-2/-/-pyrazol-3-yl)-propylamine C in a highly regioselective manner.
- Primary amine C was then acylated with carboxylic acid derivative D to give the acyclic amide E which was transformed into the cyclic seven-membered imine F via Bischler-Napieralski reaction.
- Subsequent imine reduction gave the secondary amine precursor G which was finally ⁇ /-alkylated with electrophile IH in order to obtain the final orexin receptor antagonists M.
- R 1 , R 2 , R 3 , R 4 , R 5 and Y are as defined in general formula Il above, and Z represents Br or OTs;
- Z represents Br or OTs;
- the secondary amine G could be ⁇ /-alkylated with ester derivative J (instead of amide derivative IH) to give intermediate K which can either be directly transformed into the final compounds Il by reaction with an amine derivative L or which can be first hydrolyzed to the corresponding carboxylic acid M followed by reaction with an amine L to give final compounds M.
- 3-(2-ethyl-5- methyl-2/-/-pyrazol-3-yl)-propylamine 10 can be acylated with the hydrocinnamic acid derivative 14 in presence of PyBOP giving the amide derivative 15.
- the resulting solution was further stirred at 0°C, under nitrogen, for 1 h15. After concentration to dryness under reduced pressure, dichloromethane (50 ml), and water (50 ml) were successively added. The aqueous layer was further extracted with dichloromethane (25 ml). The mixed organic extracts were dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The resulting crude was purified by flash chromatography (silicagel; DCM / MeOH / 25% aq.
- reaction mixture was heated to 70°C, under nitrogen, for 23h. Then the reaction mixture was cooled to rt, the solvent was removed under vacuum, dichloromethane (80 ml) was added, and the solution was washed with brine (2 x 80 ml). The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure.
- reaction mixture was heated to 70°C, under nitrogen, for 23h. Then the reaction mixture was cooled to rt, the solvent was removed under vacuum, dichloromethane (80 ml) was added, and the solution was washed with brine (2 x 80 ml). The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure.
- reaction mixture was heated to 70°C, under nitrogen, for 24h. Then the reaction mixture was cooled to rt, the solvent was removed under vacuum, dichloromethane (50 ml) was added, and the solution was washed with brine (50 ml). The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure.
- reaction mixture was cooled to rt, the solvent was removed under vacuum, dichloromethane (80 ml) was added, and the solution was washed with brine (2 x 80 ml). The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure.
- the orexin receptor antagonistic activity of the compounds of formula (II) is determined in accordance with the following experimental method.
- Chinese hamster ovary (CHO) cells expressing the human orexin-1 receptor and the human orexin-2 receptor, respectively, are grown in culture medium (Ham F- 12 with L-Glutamine) containing 300 ⁇ g/ml G418, 100 U/ml penicillin, 100 ⁇ g/ml streptomycin and 10 % inactivated fetal calf serum (FCS).
- FCS fetal calf serum
- the cells are seeded at 80'0OO cells / well into 96-well black clear bottom sterile plates (Costar) which have been precoated with 1 % gelatine in Hanks' Balanced Salt Solution (HBSS). All reagents are from Gibco BRL.
- the seeded plates are incubated overnight at 37°C in 5% CO 2 .
- Human orexin-A as an agonist is prepared as 1 mM stock solution in methanol: water (1 :1 ), diluted in HBSS containing 0.1 % bovine serum albumin (BSA) and 2 mM HEPES for use in the assay at a final concentration of 10 nM.
- BSA bovine serum albumin
- Antagonists are prepared as 10 mM stock solution in DMSO, then diluted in 96- well plates, first in DMSO, then in HBSS containing 0.1 % bovine serum albumin (BSA) and 2 mM HEPES. On the day of the assay, 100 ⁇ l of loading medium (HBSS containing 1 % FCS, 2 mM HEPES, 5 mM probenecid (Sigma) and 3 ⁇ M of the fluorescent calcium indicator fluo-3 AM (1 mM stock solution in DMSO with 10% pluronic acid) (Molecular Probes) is added to each well.
- BSA bovine serum albumin
- the 96-well plates are incubated for 60 min at 37° C in 5% CO 2 .
- the loading solution is then aspirated and cells are washed 3 times with 200 ⁇ l HBSS containing 2.5 mM probenecid, 0.1 % BSA, 2 mM HEPES. 100 ⁇ l of that same buffer is left in each well.
- antagonists are added to the plate in a volume of 50 ⁇ l, incubated for 20 min and finally 100 ⁇ l of agonist is added. Fluorescence is measured for each well at 1 second intervals, and the height of each fluorescence peak is compared to the height of the fluorescence peak induced by 10 nM orexin-A with buffer in place of antagonist. For each antagonist, IC 50 value (the concentration of compound needed to inhibit 50 % of the agonistic response) is determined. Antagonistic activities of compounds are in the nanomolar range with respect to OX1 and OX 2 receptors. Selected compounds are displayed in Table 1.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07826141A EP2059520B1 (en) | 2006-08-28 | 2007-08-27 | 1,4,5,6,7,8-hexahydro-i,2,5-triaza-azulene derivatives as orexin receptor antagonists |
CA002659352A CA2659352A1 (en) | 2006-08-28 | 2007-08-27 | 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulene derivatives as orexin receptor antagonists |
DE602007004999T DE602007004999D1 (en) | 2006-08-28 | 2007-08-27 | 1,4,5,6,7,8-HEXAHYDRO-1,2,5-TRIAZA AZULEN DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS |
US12/439,303 US20100029617A1 (en) | 2006-08-28 | 2007-08-27 | 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulene derivatives as orexin receptor antagonists |
JP2009526234A JP2010502587A (en) | 2006-08-28 | 2007-08-27 | 1,4,5,6,7,8-Hexahydro-1,2,5-triaza-azulene derivatives as orexin receptor antagonists |
AT07826141T ATE458740T1 (en) | 2006-08-28 | 2007-08-27 | 1,4,5,6,7,8-HEXAHYDRO-1,2,5-TRIAZA-AZULENE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IB2006052984 | 2006-08-28 | ||
IBPCT/IB2006/052984 | 2006-08-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008026149A1 true WO2008026149A1 (en) | 2008-03-06 |
Family
ID=38951714
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2007/053417 WO2008026149A1 (en) | 2006-08-28 | 2007-08-27 | 1,4,5,6, 7,8-hexahydro-i^1s-triaza-azulene derivatives as orexin receptor antagonists |
Country Status (9)
Country | Link |
---|---|
US (1) | US20100029617A1 (en) |
EP (1) | EP2059520B1 (en) |
JP (1) | JP2010502587A (en) |
CN (1) | CN101511833A (en) |
AT (1) | ATE458740T1 (en) |
CA (1) | CA2659352A1 (en) |
DE (1) | DE602007004999D1 (en) |
ES (1) | ES2339822T3 (en) |
WO (1) | WO2008026149A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008147518A1 (en) | 2007-05-23 | 2008-12-04 | Merck & Co., Inc. | Pyridyl piperidine orexin receptor antagonists |
WO2009021740A2 (en) | 2007-08-15 | 2009-02-19 | Sanofis-Aventis | Substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments |
US9156819B2 (en) | 2011-10-19 | 2015-10-13 | Merck Sharp & Dohme Corp. | 2-pyridyloxy-4-nitrile orexin receptor antagonists |
US9440982B2 (en) | 2012-02-07 | 2016-09-13 | Eolas Therapeutics, Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
US9499517B2 (en) | 2012-02-07 | 2016-11-22 | Eolas Therapeutics, Inc. | Substituted prolines / piperidines as orexin receptor antagonists |
WO2017194548A1 (en) | 2016-05-10 | 2017-11-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases |
US10221170B2 (en) | 2014-08-13 | 2019-03-05 | Eolas Therapeutics, Inc. | Difluoropyrrolidines as orexin receptor modulators |
US10828302B2 (en) | 2016-03-10 | 2020-11-10 | Janssen Pharmaceutica Nv | Methods of treating depression using orexin-2 receptor antagonists |
US10894789B2 (en) | 2016-02-12 | 2021-01-19 | Astrazeneca Ab | Halo-substituted piperidines as orexin receptor modulators |
US11059828B2 (en) | 2009-10-23 | 2021-07-13 | Janssen Pharmaceutica Nv | Disubstituted octahydropyrrolo[3,4-C]pyrroles as orexin receptor modulators |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010513466A (en) * | 2006-12-22 | 2010-04-30 | アクテリオン ファーマシューティカルズ リミテッド | 5,6,7,8-tetrahydro-imidazo [1,5-A] pyrazine derivatives |
CN102076694A (en) * | 2008-06-25 | 2011-05-25 | 埃科特莱茵药品有限公司 | 5, 6, 7, 8-tetrahydro-imidazo[1, 5-a]pyrazine compounds |
KR20230043227A (en) * | 2016-05-12 | 2023-03-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Methods of treating circadian rhythm sleep disorders |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002051838A1 (en) * | 2000-12-27 | 2002-07-04 | Actelion Pharmaceuticals Ltd. | Novel benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonists |
WO2004004733A1 (en) * | 2002-07-09 | 2004-01-15 | Actelion Pharmaceuticals Ltd. | 7,8,9,10-tetrahydro-6h-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2h-pyrrolo[2,1-b]-quinazolinone derivatives |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA02008797A (en) * | 2000-03-14 | 2005-09-08 | Actelion Pharmaceuticals Ltd | 1,2,3,4 tetrahydroisoquinoline derivatives. |
WO2001085693A1 (en) * | 2000-05-11 | 2001-11-15 | Banyu Pharmaceutical Co., Ltd. | N-acyltetrahydroisoquinoline derivatives |
EP1637521B1 (en) * | 2003-06-23 | 2013-06-19 | Ono Pharmaceutical Co., Ltd. | Novel tricyclic heterocycle compound |
DK1668014T3 (en) * | 2003-09-17 | 2009-04-20 | Janssen Pharmaceutica Nv | Condensed heterocyclic compounds as serotonin receptor modulators |
WO2007122591A2 (en) * | 2006-04-26 | 2007-11-01 | Actelion Pharmaceuticals Ltd | Pyrazolo-tetrahydro pyridine derivatives as orexin receptor antagonists |
-
2007
- 2007-08-27 JP JP2009526234A patent/JP2010502587A/en active Pending
- 2007-08-27 WO PCT/IB2007/053417 patent/WO2008026149A1/en active Application Filing
- 2007-08-27 CA CA002659352A patent/CA2659352A1/en not_active Abandoned
- 2007-08-27 EP EP07826141A patent/EP2059520B1/en not_active Not-in-force
- 2007-08-27 US US12/439,303 patent/US20100029617A1/en not_active Abandoned
- 2007-08-27 DE DE602007004999T patent/DE602007004999D1/en active Active
- 2007-08-27 AT AT07826141T patent/ATE458740T1/en not_active IP Right Cessation
- 2007-08-27 CN CNA2007800321316A patent/CN101511833A/en active Pending
- 2007-08-27 ES ES07826141T patent/ES2339822T3/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002051838A1 (en) * | 2000-12-27 | 2002-07-04 | Actelion Pharmaceuticals Ltd. | Novel benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonists |
WO2004004733A1 (en) * | 2002-07-09 | 2004-01-15 | Actelion Pharmaceuticals Ltd. | 7,8,9,10-tetrahydro-6h-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2h-pyrrolo[2,1-b]-quinazolinone derivatives |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8242121B2 (en) | 2007-05-23 | 2012-08-14 | Merck Sharp & Dohme Corp. | Pyridyl piperidine orexin receptor antagonists |
US8569311B2 (en) | 2007-05-23 | 2013-10-29 | Merch Sharp & Dohme Corp. | Pyridyl piperidine orexin receptor antagonists |
WO2008147518A1 (en) | 2007-05-23 | 2008-12-04 | Merck & Co., Inc. | Pyridyl piperidine orexin receptor antagonists |
WO2009021740A2 (en) | 2007-08-15 | 2009-02-19 | Sanofis-Aventis | Substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments |
US11059828B2 (en) | 2009-10-23 | 2021-07-13 | Janssen Pharmaceutica Nv | Disubstituted octahydropyrrolo[3,4-C]pyrroles as orexin receptor modulators |
US11667644B2 (en) | 2009-10-23 | 2023-06-06 | Janssen Pharmaceutica Nv | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators |
US9156819B2 (en) | 2011-10-19 | 2015-10-13 | Merck Sharp & Dohme Corp. | 2-pyridyloxy-4-nitrile orexin receptor antagonists |
US9896452B2 (en) | 2012-02-07 | 2018-02-20 | Eolas Therapeutics, Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
US9499517B2 (en) | 2012-02-07 | 2016-11-22 | Eolas Therapeutics, Inc. | Substituted prolines / piperidines as orexin receptor antagonists |
US9440982B2 (en) | 2012-02-07 | 2016-09-13 | Eolas Therapeutics, Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
US10221170B2 (en) | 2014-08-13 | 2019-03-05 | Eolas Therapeutics, Inc. | Difluoropyrrolidines as orexin receptor modulators |
US10894789B2 (en) | 2016-02-12 | 2021-01-19 | Astrazeneca Ab | Halo-substituted piperidines as orexin receptor modulators |
US11434236B2 (en) | 2016-02-12 | 2022-09-06 | Astrazeneca Ab | Halo-substituted piperidines as orexin receptor modulators |
US10828302B2 (en) | 2016-03-10 | 2020-11-10 | Janssen Pharmaceutica Nv | Methods of treating depression using orexin-2 receptor antagonists |
US11241432B2 (en) | 2016-03-10 | 2022-02-08 | Janssen Pharmaceutica Nv | Methods of treating depression using orexin-2 receptor antagonists |
WO2017194548A1 (en) | 2016-05-10 | 2017-11-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases |
Also Published As
Publication number | Publication date |
---|---|
JP2010502587A (en) | 2010-01-28 |
CA2659352A1 (en) | 2008-03-06 |
CN101511833A (en) | 2009-08-19 |
ATE458740T1 (en) | 2010-03-15 |
ES2339822T3 (en) | 2010-05-25 |
US20100029617A1 (en) | 2010-02-04 |
EP2059520A1 (en) | 2009-05-20 |
EP2059520B1 (en) | 2010-02-24 |
DE602007004999D1 (en) | 2010-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2059520B1 (en) | 1,4,5,6,7,8-hexahydro-i,2,5-triaza-azulene derivatives as orexin receptor antagonists | |
EP2013209B1 (en) | Pyrazolo-tetrahydropyridine derivatives as orexin receptor antagonists | |
EP2125823B1 (en) | 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives | |
RU2478099C2 (en) | 2-aza-bicyclo[3,3,0]octane derivatives | |
US8742106B2 (en) | Disubstituted heteroaryl-fused pyridines | |
US20110086889A1 (en) | Tetrazole compounds as orexin receptor antagonists | |
US20110039857A1 (en) | Piperidine and pyroolidine compounds | |
CA2699328A1 (en) | Pyrrolidines and piperidines as orexin receptor antagonists | |
CA2669060A1 (en) | Piperidine compounds | |
US10738031B2 (en) | N-[(heteroaryloxy)propanyl]heteroaryl carboxamides as antagonists of orexin subtype 1 receptor activity | |
US20110105514A1 (en) | 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine compounds | |
WO2017178343A1 (en) | Novel n-[(pyrimidinylamino)propanyl]-and n-[(pyridinylamino)propanyl]arylcarboxamides | |
WO2017178340A1 (en) | Novel n-[(pyridyloxy)propanyl]benzamides | |
EP3442967A1 (en) | Novel n-[(pyrimidinyloxy)propanyl]benzamides | |
WO2017178339A1 (en) | Novel n-[(pyrazinyloxy)propanyl]benzamides | |
EP3442966A1 (en) | Noveln |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780032131.6 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07826141 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007826141 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2659352 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009526234 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12439303 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
NENP | Non-entry into the national phase |
Ref country code: RU |